Non Small Cell Lung Cancer News and Research

RSS

Non-Small Cell Lung Cancers are a group of lung cancers that are named for the kinds of cells found in the cancer and how the cells look under a microscope. The three main types of non-small cell lung cancer are squamous cell carcinoma, large cell carcinoma, and adenocarcinoma. Non-small cell lung cancer is the most common kind of lung cancer.

Daraxonrasib shows durable responses in RAS-mutant lung cancer

Daraxonrasib, an oral RAS inhibitor therapy, achieved durable responses in pretreated patients with RAS-mutant non-small cell lung cancer (NSCLC) in a Phase 1/2 trial led by The University of Texas MD Anderson Cancer Center.

2 Sep 2026

Post-surgery immunotherapy may not benefit specific lung cancer patients

A new real-world observational study has found that adding adjuvant immunotherapy after surgery does not significantly improve survival outcomes in patients with resectable non-small cell lung cancer (NSCLC) who have already achieved a pathological complete response (pCR) following neoadjuvant chemoimmunotherapy.

2 Sep 2026

Immunotherapy shows potential for treating rising gynecological tumors

Gynecological tumors, including cervical cancer (CC), endometrial cancer (EC), and ovarian cancer (OC), represent a significant global health burden for women.

1 Sep 2026

AI tools map tumor architecture to predict treatment response

Spatial transcriptomics is a powerful tool to create a detailed map of not just how genes are expressed in a piece of tissue, but also where genetic activity takes place in different cells and locations within the tissue.

31 Aug 2026

Protecting the thymus may improve lung cancer treatment outcomes

Building on recent discoveries about the adult thymus, Mass General Brigham investigators used artificial intelligence to show that incidental radiation exposure to the thymus may influence outcomes in patients with lung cancer.

25 Aug 2026

Study links thymus radiation to worse lung cancer outcomes

Until recently, the thymus was thought to be of little use beyond puberty, but new research has shown that radiation to the organ is associated with worse outcomes in patients being treated for non-small cell lung cancer (NSCLC).

25 Aug 2026

A striking immune cell pattern emerges around a person’s 100th birthday

Single-cell immune profiling found that CD4 cytotoxic T lymphocytes become more abundant around age 100, showing stepwise differentiation and substantial clonal expansion. Ex vivo experiments also revealed cytokine plasticity within individual clones, supporting the hypothesis that these cells adapt to persistent antigens during healthy aging, although their direct role in longevity remains unproven.

23 Aug 2026

Younger lung cancer patients show more targetable gene alterations

Younger adults with non-small cell lung cancer are significantly more likely than older patients to have genetic alterations that can be matched with targeted therapies, according to a large international study led in part by researchers at Sylvester Comprehensive Cancer Center part of the University of Miami Miller School of Medicine.

21 Aug 2026

New AI framework improves reliability of cancer pathology diagnosis

Cancer diagnoses directly affect treatment decisions and prognosis and can even have life-altering consequences.

20 Aug 2026

PolyU develops AI Virtual Patient Simulation System for precision cancer care

A research team at The Hong Kong Polytechnic University (PolyU) has developed a patient-centric "Artificial Intelligence (AI) Virtual Patient Simulation System", overcoming the limitations of conventional static diagnosis.

14 Aug 2026

New drug delivers promising survival gains in pancreatic cancer

About 90% of people with pancreatic cancer have pancreatic ductal adenocarcinoma (PDAC), which is driven by an activating mutation in the KRAS gene.

9 Aug 2026

Obscure X chromosome protein emerges as key driver in several cancers

A little-known protein encoded on the X chromosome is attracting growing attention for its potential role in cancer development and treatment.

5 Aug 2026

RNA-based testing can improve detection of key lung cancer biomarkers

New research has shown that RNA-based testing can improve the detection and interpretation of clinically actionable genomic alterations leading to MET exon 14 skipping in lung cancer patients—important biomarkers that may be missed by DNA-only approaches.

23 Jul 2026

City of Hope launches trial to map how tumors change during immunotherapy resistance

City of Hope®, one of the largest and most advanced cancer research and treatment organizations in the United States with its National Medical Center ranked among the nation's top cancer centers by U.S. News & World Report, has opened an innovative Phase 2 clinical trial designed to map how tumors change as they begin to resist immunotherapy, treatment that improves the immune system's ability to fight disease.

21 Jul 2026

Combination treatment strategy uses cells' waste removal functions to dismantle multiple myeloma

New research out of VCU Massey Comprehensive Cancer Center provides promising evidence for an innovative combination treatment strategy that uses cells' waste removal functions to effectively dismantle multiple myeloma.

13 Jul 2026

New approach accurately predicts lung cancer mutations

Scientists have developed a new method for accurately predicting gene changes that cause lung cancer, without the need for slower, more expensive lab techniques.

13 Jul 2026

Microbiome science merges with oncology for better cancer treatments

Cancer remains notoriously difficult to treat, partly because tumors co‑opt their surrounding environment, including the resident microbiota, to evade immune surveillance and resist conventional therapies.

7 Jul 2026

Targeted therapy doubles progression-free survival in rare bile duct cancer

Results of the ongoing eNRGy trial, a single-arm, multicenter, global phase 2 clinical trial evaluating zenocutuzumab in solid tumors positive for Neuregulin 1 (NRG1) gene fusions, reported manageable side effects and clinically meaningful efficacy – including a near doubling of progression-free survival compared to expectations with standard of care – in previously treated patients with advanced NRG1-positive cholangiocarcinoma.

2 Jul 2026

Lipid nanoparticles enhance immune response against lung cancer

Researchers at the University of Arizona R. Ken Coit College of Pharmacy have developed a new strategy that helps the immune system recognize and attack lung cancer tumors more effectively.

25 Jun 2026

Targeting metabolic pathways could prevent relapse in KRAS-mutant cancers

Our cells rely on tightly regulated signaling pathways to control when they grow, divide, and survive. When these regulatory systems are disrupted, cells can acquire the ability to grow uncontrollably and become cancerous.

25 Jun 2026